drugset / Trial / NCT06249438
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy
Timeline
- Start
- 2024-03-20
- Primary completion
- 2027-03
- Completion
- 2040-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C-CAR168 | Cell therapy | — | Intravenous |